MWNA
SBBP

Marshall Wace North America’s Strongbridge Biopharma plc. SBBP Stock Holding History

Marshall Wace North America’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,870
Closed -$58K – 1710
2018
Q3 		$58K Sell
11,870
-40,676
-77% -$208K ﹤0.01% 877
2018
Q2 		$315K Buy
+52,546
New +$384K ﹤0.01% 1174

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Marshall Wace North America's SBBP Position: Q4 2018 in Review

Marshall Wace North America sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2018, closing a stake of 11,870 shares — an estimated $58K sold.

Marshall Wace North America first reported a position in SBBP in Q2 2018 and held it in 2 quarters. The position peaked at $315K in Q2 2018. 42 funds tracked by Wall St. Rank hold SBBP as of Q4 2018.

  • Marshall Wace North America reported no remaining Strongbridge Biopharma plc. position as of Q4 2018 after selling out during the quarter.
  • Marshall Wace North America sold 11,870 Strongbridge Biopharma plc. shares in Q4 2018, an estimated $58K.
  • Marshall Wace North America first reported a position in Strongbridge Biopharma plc. in Q2 2018 and held it in 2 quarters.
  • Marshall Wace North America's Strongbridge Biopharma plc. position peaked at $315K in Q2 2018.
  • 42 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2018.

Based on Marshall Wace North America's 13F filing for Q4 2018, filed 14 Feb 2019.